- Alcohol metabolites (EtG, EtS)
- Alcohol biomarkers (PEth)
- Amphetamines
- Amphetamines, with reflex to d-methamphetamine (dextromethamphetamine) and l-methamphetamine (levomethamphetamine) isomers
- Antidepressants
- Antipsychotics (urine)
- Antipsychotics (serum)
- Barbiturates
- Benzodiazepines
Centralize drug testing to optimize efficiency, spend, and patient care
For health systems, controlling costs and ensuring accurate patient test history can be challenging. This is especially true when multiple providers—primary care providers, pain specialists, etc—are involved in caring for a patient, prescribing medications, and sometimes duplicating test requests.
Consolidating testing with Quest provides centralized access and visibility to test ordering and results through the EHR system. This can deliver system-wide insights to inform changes to drug monitoring protocols, risk mitigation, test stewardship, and more.
Our comprehensive drug test menu covers a broad range of substances
Our broad menu of drug tests covers substances that patients take to address chronic pain, anxiety, depression, ADHD, or substance use disorder—whether those substances are prescribed, nonprescribed, or illicit.
Our single drug test options and panels include tests for pain medications, stimulants, sedatives, antidepressants, antipsychotics, opioids, other controlled substances, and illicit drugs. We also offer a wide range of panels that screen for several different combinations of drugs and medications.
Flexible testing solutions let you choose the right test for each patient
Best practices include presumptive testing with confirmation of positives with definitive testing, as well as direct-to-definitive testing when a presumptive test for a specific drug is not available. This helps minimize overtesting while providing the right level of information needed to make informed decisions.
Quest offers broad presumptive test offerings to quickly rule out multiple drug classes, and definitive testing for confirmation of presumptive positive results and for testing where presumptive tests are not available.
Get more actionable insights with definitive drug testing options
Definitive drug tests are used to identify specific drugs/metabolites present. Definitive testing has high sensitivity and is used to confirm or refute presumptive test results, helping to reduce the occurrence of false-positive/false-negative results.
We offer definitive drug testing as individual tests or panels, including a comprehensive panel that provides additional insights.
- Tests for 7 most commonly ordered controlled Rx medications and illicit/misused substances
- Clinical settings include primary care, OBGYN, pain management
- Tests for controlled Rx medications, including medication-assisted treatment (MAT) drugs and illicit/misused substances
- Clinical settings include primary care, OBGYN, pain management
- Tests for extended controlled Rx medications, including MAT drugs and illicit/misused substances
- Clinical settings include healthcare providers requiring a larger panel in nonemergency settings
- Tests for 113 relevant drugs including Rx and over-the-counter medications, illicit substances, and commonly misused substances
- Clinical settings include broad-spectrum panel for emergency and hospital settings
Our most extensive panel offers more test insights:
Why choose Quest for presumptive and definitive drug testing solutions?
Quest is an industry leader in clinical drug monitoring and research and can support health systems through responsible drug testing that helps manage the dual drug misuse and mental health crises.
Novel Psychoactive Substances (NPS) Panel now available
Quest now offers definitive NPS testing, which simultaneously identifies a broad array of NPS classes. The panel uses definitive liquid chromatography with tandem mass spectrometry (LC-MS/ MS)-based testing to establish NPS misuse. Using data from public safety, law enforcement, research organizations, and internal surveillance, the panel is updated periodically and evaluated at least annually, ensuring inclusion of the most relevant and prevalent substances without having to change the test code.
2023 Quest Diagnostics Health Trends®
report on the growing crisis of novel psychoactive substances
Contact us
Want to learn more about how clinical drug
monitoring can help provide critical insights?
Let’s get in touch.
Lab Tests by Specialty links
Clinical drug monitoring
Our broad drug monitoring portfolio includes
presumptive and definitive test options
- Site map
- Privacy Notices
- Terms
- Contact us
- Language assistance / non-discrimination
- Asistencia de idiomas / Aviso de no discriminación
- 語言協助 / 不歧視通知
- Accessibility
-
Your Privacy Choices
Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services. Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services.
Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.